Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 Nov;25(11):1153-1158.
doi: 10.1089/jwh.2015.5674. Epub 2016 Oct 18.

Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women

Dana Whittemore  1 , Lili Ding  1   2 , Lea E Widdice  1   2 , Darron A Brown  3 , David I Bernstein  1   2 , Eduardo L Franco  4 , Jessica A Kahn  1   2
Affiliations
Multicenter Study

Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women

Dana Whittemore et al. J Womens Health (Larchmt). 2016 Nov.

Abstract

Background: Previous studies have demonstrated racial and ethnic differences in the distribution of human papillomavirus (HPV) types among adult women with cervical precancers. The aim of this study was to determine whether the distribution of vaccine-targeted HPV types varies by race/ethnicity among unvaccinated young women.

Materials and methods: A secondary analysis was performed using data from four studies of sexually experienced, unvaccinated, 13-26-year-old women. Participants completed surveys and provided a cervicovaginal swab for HPV DNA testing. Multivariable logistic regression analyses were performed to examine whether race, ethnicity, and other factors were associated with type-specific HPV infection among the overall sample and among HPV-infected participants. Models controlled for age, HPV knowledge, sexual behaviors, substance use, and random study effect.

Results: The mean age of participants (N = 841) was 19.3 years; 64.4% were black and 8.9% Hispanic. Black women were more likely than white women to be positive for ≥1 HPV type (odds ratio [OR] 1.83, 95% CI 1.30-2.58) and Hispanic women were less likely than non-Hispanic women to be positive for ≥1 HPV type (OR 0.47, 95% CI 0.24-0.92). However, among all young women and HPV-infected women, neither race nor ethnicity was associated with positivity for HPV types targeted by the following vaccines: 2-valent (HPV16 and/or 18), 4-valent (HPV6, 11, 16, and/or 18), or 9-valent (HPV6, 11, 16, 18, 31, 33, 45, 52, and/or 58).

Conclusion: The prevalence of HPV types targeted by the 2-valent, 4-valent, and 9-valent vaccines did not differ by race or ethnicity among all and among HPV-infected women in this sample.

Keywords: epidemiology; ethnicity; human papillomavirus; race; vaccine.

PubMed Disclaimer

Conflict of interest statement

Author Disclosure Statement Dr. Kahn has co-chaired two NIH-funded HPV vaccine clinical trials in HIV-infected individuals, for which Merck & Co., Inc., provided vaccine and immunogenicity titers. Dr. Kahn chaired a grant review committee for the Society for Adolescent Health and Medicine evaluating public health demonstration project proposals to improve adolescent vaccination; grant funding for this program was from Merck, Inc. Dr. Franco has served as occasional advisor to companies involved with HPV vaccination (Merck, GSK) and HPV and cervical cancer diagnostics (Roche, BD, Qiagen). His institution has received unconditional funding from Merck for investigator-initiated studies carried out in his unit. Dr. Brown has received honoraria and grant support from Merck, and his institution Indiana University and Merck have a confidential agreement that pays the University based on certain landmarks of vaccine development; Dr. Brown receives a portion of this money as income. For the remaining authors, no competing financial interests exist.

References

    1. Hariri S, Unger ER, Sternberg M, et al. . Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003–2006. J Infect Dis 2011;204:566–573 - PubMed
    1. Bouvard V, Baan R, Straif K, et al. . A review of human carcinogens—Part B: Biological agents. Lancet Oncol 2009;10:321–322 - PubMed
    1. Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008;17:1611–1622 - PMC - PubMed
    1. Guan P, Howell-Jones R, Li N, et al. . Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int J Cancer 2012;131:2349–2359 - PubMed
    1. Van de Velde N, Boily MC, Drolet M, et al. . Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: A model-based analysis. J Natl Cancer Inst 2012;104:1712–1723 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources